What is a Patient Information Leaflet and why is it useful?

The Patient Information Leaflet (PIL) is the leaflet included in the pack with a medicine. It is written for patients and gives information about taking or using a medicine. It is possible that the leaflet in your medicine pack may differ from this version because it may have been updated since your medicine was packaged.

Below is a text only representation of the Patient Information Leaflet. The original can be viewed in PDF format using the link above.

The text only version may be available from RNIB in large print, Braille or audio CD. For further information call RNIB Medicine Leaflet Line on 0800 198 5000. The product code(s) for this leaflet are: EU/1/14/936/001 , EU/1/14/936/002, EU/1/14/936/003, EU/1/14/936/004, EU/1/14/936/005, EU/1/14/936/006, EU/1/14/936/007.

Nuwiq powder and solvent for solution for injection.

Package leaflet: Information for the user

Nuwiq 250 IU powder and solvent for solution for injection

Nuwiq 500 IU powder and solvent for solution for injection

Nuwiq 1000 IU powder and solvent for solution for injection

Nuwiq 2000 IU powder and solvent for solution for injection

Nuwiq 2500 IU powder and solvent for solution for injection

Nuwiq 3000 IU powder and solvent for solution for injection

Nuwiq 4000 IU powder and solvent for solution for injection

simoctocog alfa (recombinant human coagulation factor VIII)

Read all of this leaflet carefully before you start using this medicine because it contains important information for you.

  • Keep this leaflet. You may need to read it again.
  • If you have any further questions, ask your doctor.
  • This medicine has been prescribed for you only. Do not pass it on to others. It may harm them, even if their signs of illness are the same as yours.
  • If you get any side effects, talk to your doctor. This includes any possible side effects not listed in this leaflet. See section 4.

What is in this leaflet

1. What Nuwiq is and what it is used for
2. What you need to know before you use Nuwiq
3. How to use Nuwiq
4. Possible side effects
5. How to store Nuwiq
6. Contents of the pack and other information

1. What Nuwiq is and what it is used for

Nuwiq contains the active substance human recombinant coagulation factor VIII (simoctocog alfa). Factor VIII is necessary for the blood to form clots and stop bleeding. In patients with haemophilia A (inborn factor VIII deficiency), factor VIII is missing or not working properly.

Nuwiq replaces the missing factor VIII and is used for treatment and prevention of bleeding in patients with haemophilia A and can be used for all age groups.

2. What you need to know before you use Nuwiq

Do not use Nuwiq:

  • if you are allergic to the active substance simoctocog alfa or any of the other ingredients of this medicine (listed in section 6).

If you are unsure about this, ask your doctor.

Warnings and precautions

Talk to your doctor before using Nuwiq.

There is a rare chance that you may experience an anaphylactic reaction (a severe, sudden allergic reaction) to Nuwiq. You should be aware of the early signs of allergic reactions as they are listed in section 4 “Allergic reactions”.

If any of these symptoms occur, stop the injection immediately and contact your doctor.

The formation of inhibitors (antibodies) is a known complication that can occur during treatment with all factor VIII medicines. These inhibitors, especially at high levels, stop the treatment working properly and you or your child will be monitored carefully for the development of these inhibitors. If you or your child´s bleeding is not being controlled with Nuwiq, tell your doctor immediately.

Cardiovascular events

In patients with existing cardiovascular risk factors, substitution therapy with FVIII may increase the cardiovascular risk.

Catheter-related complications

If you require a central venous access device (CVAD), risk of CVAD-related complications including local infections, presence of bacteria in the blood and catheter site thrombosis should be considered.

It is strongly recommended that every time that Nuwiq is administered, the name and batch number of the product are recorded in order to maintain a link between you and the batch of the medicinal product.

Other medicines and Nuwiq

Tell your doctor if you are using, have recently used or might use any other medicines.

Pregnancy and breast-feeding

If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor for advice before using this medicine.

Driving and using machines

Nuwiq has no influence on your ability to drive and use machines.

Nuwiq contains sodium

This medicine contains less than 1 mmol sodium (23 mg) per vial, that is to say essentially ‘sodium-free’.

However, depending on your body weight and your dose of Nuwiq, you could receive more than one vial. This should be taken into consideration if you are on a controlled sodium diet.

3. How to use Nuwiq

Treatment with Nuwiq will be started by a doctor who is experienced in the care of patients with haemophilia A. Always use this medicine exactly as your doctor or nurse has told you. Check with your doctor or nurse if you are not sure.

Nuwiq is usually injected into a vein (intravenously) by your doctor or a nurse who are experienced in the care of patients with haemophilia A. You or someone else might also give your Nuwiq injection, but only after receiving adequate training.

Your doctor will calculate your dose of Nuwiq (in international units = IU) depending on your condition and body weight, and on whether it is used for prevention or treatment of bleeding. How often you need an injection will depend on how well Nuwiq is working for you. Usually, treatment for haemophilia A is a life-long treatment.

Prevention of bleeding

The usual dose of Nuwiq is 20 to 40 IU per kg body weight, given every 2 to 3 days. However, in some cases, especially in younger patients, more frequent injections or higher doses may be necessary.

Treatment of bleeding

The dose of Nuwiq is calculated depending on your body weight and the factor VIII levels to be achieved. The target factor VIII levels will depend on the severity and location of the bleeding.

If you have the impression that the effect of Nuwiq is insufficient, talk to your doctor. Your doctor will perform appropriate laboratory tests to make sure that you have adequate factor VIII levels. This is particularly important if you are having major surgery.

Patients developing factor VIII inhibitors

If your plasma factor VIII fails to reach expected levels with Nuwiq, or if bleeding is not adequately controlled, it could be due to the development of factor VIII inhibitors. This will be checked by your doctor. You might need a higher dose of Nuwiq or a different product to control bleedings. Do not increase the total dose of Nuwiq to control your bleeding without consulting your doctor.

Use in children and adolescents

The way Nuwiq is used in children and adolescents does not differ from the way it is used in adults. Because factor VIII products may have to be given more often in children and adolescents, a central venous access device (CVAD) may need to be fitted. A CVAD is an external connector that allows access to the bloodstream through a catheter without injection through the skin.

If you use more Nuwiq than you should

No symptoms of overdose have been reported. If you have injected more Nuwiq than you should, please inform your doctor.

If you forget to use Nuwiq

Do not take a double dose to make up for a forgotten dose. Proceed with the next dose immediately and continue as advised by your doctor.

If you stop using Nuwiq

Do not stop using Nuwiq without consulting your doctor.

If you have any further questions on the use of this medicine, ask your doctor.

4. Possible side effects

Like all medicines, this medicine can cause side effects, although not everybody gets them.

Allergic reactions

You should be aware of the early signs of allergic reactions. If severe, sudden allergic reactions (anaphylactic) occur (very rare: may affect up to 1 in 10,000 people), the injection must be stopped immediately. You must contact your doctor immediately if you notice any of the following symptoms:

  • rash, hives, wheals, generalised itching,
  • swelling of lips and tongue,
  • difficulty in breathing, wheezing, tightness in the chest,
  • general feeling of being unwell,
  • dizziness and loss of consciousness.

These symptoms can be early symptoms of an anaphylactic shock. If any of these symptoms occur, stop the injection immediately and contact your doctor. Severe symptoms require prompt emergency treatment.

Very common side effects may affect more than 1 in 10 people

Factor VIII inhibition in previously untreated patients.

For children and adolescents not previously treated with factor VIII medicines, inhibitor antibodies (see section 2) may form very commonly (more than 1 in 10 patients).

However for patients who have received previous treatment with factor VIII (more than 150 days of treatment) the risk is uncommon (less than 1 in 100 patients). If this happens, your or your child´s medicines may stop working properly and you or your child may experience persistent bleeding. If this happens, you should contact your doctor immediately.

Common side effects may affect up to 1 in 10 people

Hypersensitivity, fever.

Uncommon side effects may affect up to 1 in 100 people

Tingling or numbness (paraesthesia), headache, injection site inflammation, injection site pain, back pain, vertigo, dry mouth, haemorrhagic anaemia, non-neutralising antibody positive (in PTPs).

Reporting of side effects

If you get any side effects, talk to your doctor. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the national reporting system. By reporting side effects you can help provide more information on the safety of this medicine.

Ireland

HPRA Pharmacovigilance
Earlsfort Terrace
IRL - Dublin 2
Tel: +353 1 6764971
Fax: +353 1 6762517
Website: www.hpra.ie

United Kingdom

Yellow Card Scheme
Website: www.mhra.gov.uk/yellowcard

or search for MHRA Yellow Card in the Google Play or Apple App Store

5. How to store Nuwiq

Keep this medicine out of the sight and reach of children.

Do not use this medicine after the expiry date which is stated on the carton and vial label after EXP. The expiry date refers to the last day of that month.

Store in a refrigerator (2°C – 8°C). Do not freeze. Store vial in the original package in order to protect from light.

Before the Nuwiq powder is reconstituted, it may be kept at room temperature (up to 25°C) for a single period not exceeding 1 month. Record the date from when you start to store Nuwiq at room temperature on the product carton. Do not store Nuwiq in the refrigerator again after it has been stored at room temperature.

Use the reconstituted solution immediately after reconstitution.

Do not use the medicine in case you notice visible signs of deterioration of the tamper proof of packaging especially of the syringe and/or the vial.

Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.

6. Contents of the pack and other information

What Nuwiq contains

Powder:

  • The active substance is recombinant human coagulation factor VIII (simoctocog alfa).
    Each powder vial contains 250, 500, 1000, 2000, 2500, 3000 or 4000 IU of simoctocog alfa.
    Each reconstituted solution contains approximately 100, 200, 400, 800, 1000, 1200 or 1600 IU/mL of simoctocog alfa.
  • The other ingredients are sucrose, sodium chloride, calcium chloride dihydrate, arginine hydrochloride, sodium citrate dihydrate and poloxamer 188. See section 2, “Nuwiq contains sodium”.

Solvent:

Water for injections

What Nuwiq looks like and contents of the pack

Nuwiq is provided as powder and solvent for solution for injection. The powder is a white to off-white powder in a glass vial. The solvent is water for injections in a glass pre-filled syringe.

After reconstitution, the solution is clear, colourless and free from foreign particles.

Each pack of Nuwiq contains:

  • 1 powder vial with 250, 500, 1000, 2000, 2500, 3000 or 4000 IU simoctocog alfa
  • 1 pre-filled syringe with 2.5 mL water for injections
  • 1 vial adapter
  • 1 butterfly needle
  • 2 alcohol swabs

Marketing Authorisation Holder and Manufacturer

Octapharma AB
Lars Forssells gata 23
112 75 Stockholm
Sweden

For any information about this medicine, please contact the local representative of the Marketing Authorisation Holder:

United Kingdom
Octapharma Limited
Tel: +44 161 8373770

This leaflet was last revised in 04/2019

Detailed information on this medicine is available on the web site of the European Medicines Agency: http://www.ema.europa.eu.

20190228